Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-23-008564
Filing Date
2023-03-17
Accepted
2023-03-17 06:01:56
Documents
12
Period of Report
2023-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A onct-20230104.htm   iXBRL 8-K/A 58842
  Complete submission text file 0000950170-23-008564.txt   180982

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT onct-20230104.xsd EX-101.SCH 2467
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT onct-20230104_pre.xml EX-101.PRE 11425
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT onct-20230104_lab.xml EX-101.LAB 14270
6 EXTRACTED XBRL INSTANCE DOCUMENT onct-20230104_htm.xml XML 5121
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

EIN.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-50549 | Film No.: 23740599
SIC: 2834 Pharmaceutical Preparations